{"entity":{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","aka":["Shanghai Kechow Pharma, Inc."],"tldr":"Shanghai Kechow Pharma is a China-based pharmaceutical company running 3 late-stage cancer trials of tunlametinib, Tunlametinib and HL-085 in melanoma, colorectal cancer and rare cancers of childhood.","summary":"Shanghai Kechow Pharma, based in Shanghai, China, is a pharmaceutical company. Kechow Pharma is a Shanghai-based pharmaceutical company engaged in independent, intellectual-property-driven innovative drug research and development, focused on oncology and free-radical-related diseases. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing tunlametinib, Tunlametinib and HL-085 in melanoma, colorectal cancer and rare cancers of childhood. The largest, NCT06008106 (Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma), plans to enrol 165 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://kechowpharma.com"},{"label":"ClinicalTrials.gov: trials led by Shanghai Kechow Pharma","url":"https://clinicaltrials.gov/search?lead=Shanghai%20Kechow%20Pharma%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","colorectal","rare-childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":["kc1036","tunlametinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"pharma","website":"https://kechowpharma.com","founded":2014,"stage":"private-large","investors":[],"funding":[]},"route":"/companies/shanghai-kechow-pharma/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/"}],"drug":[{"id":"kc1036","kind":"drug","name":"KC1036","route":"/drugs/kc1036/"},{"id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/"}],"trial":[{"id":"nct06008106","kind":"trial","name":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","route":"/trials/nct06008106/"},{"id":"nct06008119","kind":"trial","name":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","route":"/trials/nct06008119/"}]}}